Table 3.
Comparative activity of 496.g3 with anti-IL-17A-specific antibodies secukinumab and ixekizumab in neutralizing IL-17A, IL-17F an IL-17A/F in an in vitro neutralization assay.
| IL-17A | IL-17A/F | IL-17F | ||||
|---|---|---|---|---|---|---|
| IC50 | IC90 | IC50 | IC90 | IC50 | IC90 | |
| Secukinumab | 45.0 | 956.2 | 525.9 | 65,535.0 | ND | ND |
| Ixekizumab | 0.4 | 2.2 | 43.2 | 91.0 | ND | ND |
| 496.g3 | 0.4 | 2.5 | 48.9 | 179.2 | 32.1 | 137.8 |
Calculation of IC50 and IC90 values for 496.g3, secukinumab and ixekizumab were determined by four parameter non-linear regression analysis for IL-17A, IL-17A/F, and IL-17F. IC50 and IC90 values are measured in ng/ml. ND, Not detectable.